Board Change

RNS Number : 1227Z

Victrex PLC

10 January 2011

 



Victrex plc

BOARD APPOINTMENT

 

The Board of Victrex plc (the "Company") is pleased to announce the appointment of Dr Pamela Kirby as a non-executive Director of the Company with effect from 9 February 2011.

Pamela Kirby, aged 57, is currently non-executive Chairman of Scynexis Inc., a privately owned chemistry focused drug discovery and development company based in the US and a non-executive Director of Smith and Nephew plc, Informa plc, and Novo-Nordisk A/S.  She was previously non-executive Chairman of Oxford Immunotec Limited, a non-executive Director of Curalogic A/S and Oscient Pharmaceuticals Corporation and the CEO of US based Quintiles Transnational Corporation.    

Anita Frew, Chairman of Victrex plc, said:

"I am delighted to welcome Pamela to the Board.  She has demonstrated outstanding success in her businesses. Her extensive background within the international medical industry, particularly relating to strategic planning and marketing will contribute significantly to our Board and the future development of the Company."

No further information in relation to Dr Pamela Kirby is required to be disclosed pursuant to Listing Rule 9.6.13R.

Dr Pamela Kirby has no beneficial interest in the share capital of the Company as at 10 January 2011.

Enquiries

Victrex plc

Anita Frew, Chairman                               0203 128 8100 (10 January 2011)

David Hummel, Chief Executive               01253 897700 (thereafter)

MHP Communications

Nick Denton / Barnaby Fry / Ian Payne     0203 128 8100 

Victrex plc is an innovative world leader in high performance materials through the manufacture of VICTREX^® PEEK™ polymer, a high performance, easy to process thermoplastic.

With over 30 years of experience, Victrex is a global manufacturer of innovative, high performance thermoplastic polymers. We work with customers and end users to deliver technology driven solutions to the challenges and opportunities they face. Our Victrex Polymer Solutions division ('VPS') focuses on our transport, industrial and electronics markets and our Invibio Biomaterial Solutions division ('Invibio') focuses on providing specialist solutions for medical device manufacturers.

 

END

 

 

BOASSIFLWFFSEIF